RBC Capital raised the firm’s price target on Vertex Pharmaceuticals (VRTX) to $420 from $408 and keeps a Sector Perform rating on the shares.

A federal judge threw out Amgen’s lawsuit against the state board empowered to set first-in-the-nation price ceilings on prescription drugs in Colorado, finding that the maker of arthritis medication ...

The 12-month price targets assessed by analysts reveal further insights, featuring an average target of $478.12, a high ...

We recently published a list of 20 Most Expensive Stocks Insiders Are Dumping In March. In this article, we are going to take ...

Founded in 1996, Royalty Pharma is the largest buyer of biopharmaceutical royalties and a leading funder of innovation across the biopharmaceutical industry, collaborating with innovators from ...

Individual researchers and university leaders need to make the case for science to their elected representatives and to the public at large.

Russia may face a new wave of drugs’ shortages, particularly those, which are used for the treatment of rare diseases, as ...

For years, my son grew up as a perfectly healthy kid, despite being diagnosed with CF-related metabolic syndrome. But when he suddenly developed pancreatitis, I had a hunch it was actually related to ...

From today, the updated indication for TRIKAFTA is as follows: TRIKAFTA is indicated for the treatment of cystic fibrosis in patients aged 2 years and older who have at least one F508del mutation in ...

You've probably heard a lot about something called the Pharmaceutical Benefits Scheme — or the PBS — this week. Here are some ...

We recently published a list of 10 Best Diabetes Stocks To Buy According to Billionaires. In this article, we are going to ...